Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 543-550

  Izzi, Valerio ^a   Chiurchiu, Valerio ^a   D'Aguilio, Fabiola ^a   Palumbo, Camilla ^a   Tresoldi, Ilaria ^a   Modesti, Andrea ^a   Baldini, Patrizia M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Immunosurveillance; Macrophages; Malignant mesothelioma; Monocytes; TAMs

Indexed keywords

ARACHIDONIC ACID; INTERLEUKIN 10; NITRITE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL DIFFERENTIATION; CELL POLARITY; CELL SPECIFICITY; COLLAGEN DEGRADATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MACROPHAGE; MALIGNANT MESOTHELIOMA; MONOCYTE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL;

ARACHIDONIC ACID; CELL DIFFERENTIATION; CELL LINE; COLLAGEN; DINOPROSTONE; HUMANS; INTERLEUKIN-10; MACROPHAGES; MESOTHELIOMA; MONOCYTES; NITRIC OXIDE; PHAGOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64549110981     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000180     Document Type: Article

References (41)

1. Attanos RL and Gibbs AR: Pathology of malignant mesothelioma. Histopathology 30: 403-418, 1997.
2. Pistolesi M and Rusthoven J: Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 126: 1318-1329, 2004.
3. Palumbo C, Bei R, Procopio A and Modesti A: Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem 15: 855-867, 2008.
4. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC and Lambrecht BN: Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 27: 1086-1095, 2006.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002.
6. Kim R, Emi M and Tanabe K: Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119: 254-264, 2006.
7. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P and Mantovani A: Macrophage polarization in tumor progression. Semin Cancer Biol Epub ahead of print Mar 26, 2008.
8. Elgert KD, Alleva DG and Mullins DW: Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290, 1998.
9. Dirkx AE, Oude Egbrink MG, Wagstaff J and Griffioen AW: Monocyte/ macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80: 1183-1196, 2006.
10. Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM and Zheng L: Tumor-derived hyaluronan induces formation of immuno-suppressive macrophages through transient early activation of monocytes. Blood 110: 587-595, 2007.
11. Nabil K, Rihn B, Jaurand MC, Vignaud JM, Ripoche J, Martinet Y and Martinet N: Identification of human complement factor H as a chemotactic protein for monocytes. Biochem J 326: 377-383, 1997.
12. Martinet N, Beck G, Bernard V, Plenat F, Vaillant P, Schooneman F, Vignaud JM and Martinet Y: Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity. Cancer 70: 854-860, 1992.
13. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G and De Baetselier P: Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211: 487-501, 2006.
14. Auwerx J: The human leukemia cell line, THP-1: a multifaceted model for the study of monocyte-macrophage differentiation. Experientia 47: 22-31, 1991.
15. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T and Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26: 171-176, 1980.
16. Versnel MA, Bouts MJ, Hoogsteden HC, van der Kwast TH, Delahaye M and Hagemeijer A: Establishment of human malignant mesothelioma cell lines. Int J Cancer 44: 256-260, 1989.
17. Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T and Tada K: Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 42: 1530-1536, 1982.
18. Donchenko V, Zannetti A and Baldini PM: Insulin-stimulated hydrolysis of phosphatidylcholine by phospholipase C and phospholipase D in cultured rat hepatocytes. Biochim Biophys Acta 1222: 492-500, 1994.
19. Pèrez-Pèrez GI, Shepherd VL, Morrow JD and Blaser MJ: Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun 63: 1183-1187, 1995.
20. Kato M, Neil TK, Fearnley DB, McLellan AD, Vuckovic S and Hart DN: Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int Immunol 12: 1511-1519, 2000.
21. Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K and Shimada K: Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 36: 325-329, 2000.
22. Dennis EA, Ackermann EJ, Deems RA and Reynolds LJ: Multiple forms of phospholipase A2 in macrophages capable of arachidonic acid release for eicosanoids biosynthesis. Adv Prostaglandin Thromboxane Leukoc Res 23: 75-80, 1995.
23. Chiurchiù V, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P and Baldini PM: Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept 148: 26-32, 2008.
24. Oestvang J, Anthonsen MW and Johansen B: Role of secretory and cytosolic phospholipase A(2) enzymes is lysophosphatidyl- choline-stimulated monocyte arachidonic acid release. FEBS Lett 555: 257-262, 2003.
25. Wang MT, Honn KV and Nie D: Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 26: 525-534, 2007.
26. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW and Mitchell JB: The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19: 711-721, 1998.
27. Weigert A and Brüne B: Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric oxide 19: 95-102, 2008.
28. Frank JA, Wray CM, McAuley DF, Schwendener R and Matthay MA: Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 291: L1191-L1198, 2006.
29. Smyth MJ, Dunn GP and Schreiber RD: Cancer immuno-surveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50, 2006.
30. Seeds MC and Bass DA: Regulation and metabolism of arachidonic acid. Clin Rev Allergy immunol 17: 5-26, 1999.
31. 2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol 3: 271-277, 2006.
32. Edwards JG, Faux SP, Plummer SM, Abrams KR, Walker RA, Waller DA and O'Byrne KJ: Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 8: 1857-1862, 2002.
33. + T regulatory cell activities in lung cancer. Cancer Res 65: 5211-5220, 2005.
34. + T cells. J Clin Invest 116: 2777-2790, 2006.
35. Mocellin S and Nitti D: TNF and cancer: the two sides of the coin. Front Biosci 13: 2774-2783, 2008.
36. Carbone M and Bedrossian CW: The pathogenesis of mesothelioma. Semin Diagn Pathol 23: 56-60, 2006.
37. Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR and van Kooten C: IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 107: 4930-4937, 2006.
38. Movahedi K, Guilliams M, Van den Bossche J, van den Bergh R, Gysemans C, Beschin A, De Baetselier P and van Ginderachter JA: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244, 2008.
39. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T and Takami T: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/ macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83: 1136-1144, 2008.
40. Jodele S, Blavier L, Yoon JM and De Clerck YA: Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 25: 35-43, 2006.
41. Miselis NR, Wu ZJ, van Rooijen N and Kane AB: Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7: 788-799, 2008.